Microbix Biosystems Inc. sees a modest uptick in stock price amidst recent developments.
Microbix Biosystems Inc. (MBX.TO) experienced a 3.33% price increase in today's trading, closing at C$0.31. This week, the stock has remained steady, reflecting a year-to-date gain of 29.17%. While there were no major company announcements this week, recent headlines indicate ongoing developments within the company’s operations and financial results.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$43.83M
52W high
$0.33
52W low
$0.21
1W change
+11.30%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 25.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+25.0% Upside
Current Price
C$0.32
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
46.0%
Annualized
90-Day Vol
50.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.38
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.29 – C$0.40 |
| 60 trading days | C$0.36 | C$0.29 – C$0.45 |
| 90 trading days | C$0.38 | C$0.29 – C$0.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent increase in Microbix's stock price may signal investor interest amid incremental improvements in the company's financial performance and product offerings.
C$0.31 closing price with a 3.33% gain today.
Microbix's stock has shown resilience with a 29.17% increase year-to-date, despite ongoing operational challenges.
Bull case
Microbix's recent financial results show a 13% revenue increase in Q1 2026, suggesting a positive trend. The company's advancements in molecular pathology and test-ingredient manufacturing could strengthen its market position and revenue potential.
Bear case
Despite these positive developments, Microbix still faces challenges, including a negative profit margin of -38.6%. Its stock price remains below analyst targets, and the company's reliance on a limited product range and ongoing losses could pose risks for investors.
Recent Price Action
Microbix Biosystems Inc. closed today at C$0.31, marking a 3.33% increase. Over the past week, the stock has held steady, with no significant fluctuations in price. Year-to-date, the stock has appreciated by 29.17%, reflecting growing investor interest.
Company Developments
Advertisement
While no major company news has emerged this week, recent headlines indicate that Microbix has reported a 13% revenue growth in Q1 2026, amounting to $4.2 million. Additionally, the company has been actively presenting its molecular pathology platform, which may enhance its offerings in the health care sector.
Technical Picture
Microbix's stock is currently trading above its 50-day moving average of C$0.28 and its 200-day moving average of C$0.25, indicating a positive short- to medium-term trend. The stock has a 52-week range of C$0.21 to C$0.34, suggesting that it is currently trading at 77% of its 52-week high. With a beta of 0.57, the stock is less volatile than the broader market.
Insider Activity
There are no recent insider trading activities reported for Microbix Biosystems Inc. This lack of insider transactions may indicate stability within the company's management and operational strategy.
Price Action Summary
As of the latest close, Microbix Biosystems Inc. (MBX.TO) stands at C$0.31, reflecting a 3.33% gain today. Investors will be monitoring future developments as the company continues to navigate its growth trajectory in the health care sector.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
